Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca's heart drug Brilinta fails in trial

Drug group said blood-thinning treatment missed targets for reducing repeat stroke and heart attacks
AstraZeneca's heart drug Brilinta fails in trial
Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, but not enough to hit targets

AstraZeneca PLC (LON:AZN) said stroke treatment Brilinta was not as effective as expected in trials, hitting hopes that it would be a flagship new drug.

AstraZeneca said a study of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA), had shown the drug had not met its primary efficacy endpoint of preventing repeat attacks within 90 days.

Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, heart attack or died than those on aspirin, but the difference was not statistically significant.

AstraZeneca's executive vice-president of global medicine development and chief medical officer, Sean Bohen, said: "We will present the full analysis of the trial results, including  subgroups, at a forthcoming stroke congress and will engage with regulatory agencies on the interpretation of the data."

The so-called Socrates trial evaluated the efficacy and safety of 90-day treatment with Brilinta/Brilique versus aspirin for the prevention of major vascular events in patients over 40 years-old with an acute ischaemic stroke.

Shares in AstraZeneca fell 3.5p to 3911.5p.

 

 

 

 

 

 

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
1519933435_to-conceive-pic.jpg
March 01 2018
The health and wellbeing group, which has a broad product portfolio, had an eventful 2017,
test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use